Supply Arrangements. To the knowledge of the Company, there are no facts or circumstances that have materially adversely affected or are reasonably likely to materially adversely affect the continued supply (either for clinical purposes or in bulk) of the active ingredients of the compounds, product candidates or products of the Company or any Company Subsidiary currently used in clinical trials.
Supply Arrangements. 6.1.1 On presentation of a COPD patient care record card (Example at Attachment 2), the Key Pharmacist/Technician will ensure that the urgency of supply is confirmed and completed and that medication is provided rapidly and efficiently according to patient, carer and clinical need on an individual basis.
Supply Arrangements. 5.12.1 The energy generated from the solar plant shall be injected at the Injection Point for sale to the Procurer, through the Evacuation Infrastructure.
Supply Arrangements. There are no facts or circumstances that have caused a Company Material Adverse Effect or are reasonably likely to cause a Company Material Adverse Effect on the continued supply (either for clinical purposes or in bulk) of the active ingredients of the compounds, product candidates or products of the Company or its Subsidiaries currently used in clinical trials.
Supply Arrangements. Promptly following the date of this Agreement, the Parties shall negotiate in good faith and, following the Closing Date, shall enter into, or cause their respective affiliates to enter into, a supply agreement (the “Supply Agreement”) pursuant to which Seller or any of its affiliates shall supply the Company with Products having the formulation and presentation used in the Ongoing Trials as of the Closing Date for commercial sale, which Supply Agreement shall include the terms and conditions set forth on Exhibit B attached hereto and shall be based on drafts of the same that the Parties have exchanged prior to the date of this Agreement.
Supply Arrangements. Promptly after Neose’s election to continue the development and commercialization of the Product, to the extent that BioGeneriX has the right to do so, BioGeneriX shall transfer to Neose, upon request, all Confidential Information in its possession that is necessary for the manufacture, use or sale of the Product, except for one copy that may be retained in its confidential archives. In addition, upon the request of Neose, BioGeneriX shall use Reasonable Commercial Efforts to supply the Product, or any materials supplied by BioGeneriX, or to transfer to the Neose the technology required to manufacture the Products or required materials, in each case upon commercially reasonable terms. Neose shall use Reasonable Commercial Efforts to identify a replacement manufacturer or establish a manufacturing facility for the Product, or required materials, in a timely manner. To the extent that BioGeneriX has the right to do so, BioGeneriX shall use Reasonable Commercial Efforts to enable Neose to assume the business of producing the Product, including, without limitation: (i) providing all approvals, consents, documents and information that are necessary or desirable to permit Neose to enter into a development or supply agreement with any CMOs on substantially the same business terms as those in then in effect between BioGeneriX and such CMOs; (ii) providing all manufacturing information and descriptions of the applicable technology and processes used by BioGeneriX to manufacture the Product, in sufficient detail to permit Neose to manufacture (or have manufactured) the Product in commercial quantities in an efficient manner; (iii) providing samples of all organisms or other materials and processes used in producing the Product, or required materials; and (iv) providing such training of personnel as may be necessary to permit Neose to manufacture (or have manufactured) the Product. If for any reason BioGeneriX is not legally permitted to transfer the necessary technology or rights to Neose for these purposes, BioGeneriX will use Reasonable Commercial Efforts to otherwise make available to Neose the benefits of this Section 21.3. ******. ******.
Supply Arrangements. (a) Following the Closing, Abbott will supply Boston Scientific, on an interim and private label basis, with DES Stents. In connection with the foregoing obligation, on or prior to the Closing, the parties will enter into four interim supply agreements, each effective as of the Closing (collectively, the "Supply Agreements"). Each of the Supply Agreements shall contain pricing and other terms as provided in this Section 5.07 and other terms and conditions customary for similar supply agreements and shall cover the supply of DES Stents in the following territories (one Supply Arrangement for each territory): United States, Japan, Europe and Rest of World (each, a "Territory").
Supply Arrangements. Parent and Sellers agree to cause (a) SiTeco to sell and/or license to Columbia Lighting, Inc., a Delaware corporation, and Prescolite products at prices in effect as of the date hereof and in quantities consistent with the projected sales volumes and (b) Kim Lighting, Inc., a Delaware corporation, to Sell and/or license to XxXeco products at prices in effect as of the date hereof and in quantities consistent with the projected purchasing volume, in each case for a period of at least one year after the Closing Date and on such other terms and conditions mutually acceptable to Parent, Sellers and Buyer in accordance with supply agreements to be entered into prior to Closing (the "SiTeco Supply Agreements").
Supply Arrangements. 6.1 The energy generated from the Unit shall be injected at the Delivery Point for sale to the Procurer, through the RUMSL Internal Evacuation Infrastructure, in accordance with the Coordination Agreement.
Supply Arrangements. Section 13.2 of the Agreement is hereby deleted in its entirety and replaced with the following:
